Treating eye disease with stem cells

Article

Advanced Cell Technology has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using embryonic-stem-cell-derived retinal cells to treat patients with Stargardt?s Macular Dystrophy (SMD).

Advanced Cell Technology has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using embryonic-stem-cell-derived retinal cells to treat patients with Stargardt’s Macular Dystrophy (SMD). Degenerative retinal diseases are among the most common causes of untreatable blindness in the world and while Age-Related Macular Degeneration is the most common of these diseases, SMD is still one of the most common forms of juvenile macular blindness.

“Our research clearly shows that stem-cell-derived retinal cells can rescue visual function in animals that otherwise would have gone blind. We are hopeful that the cells will be similarly efficacious in patients,” said Dr Robert Lanza, ACT’s Chief Scientific Officer.

This treatment uses stem cells to re-create cells in the retina that support the photoreceptors. These cells, called retinal pigment epithelium, are often the first to die off in SMD and AMD, which in turn leads to loss of vision.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.